EligibleTrials

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

Recruiting · NCT06673017 · Interventional (participants receive a specific treatment) · Lead sponsor: PanTher Therapeutics

View the official record on ClinicalTrials.gov →
Pancreatic Cancer

Interventions studied

PTM-101

What this trial is about

This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).

Who can take part

Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

8 locations listed across 6 US states.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.